Christophe Quéva

2.4k total citations
43 papers, 1.7k citations indexed

About

Christophe Quéva is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Christophe Quéva has authored 43 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Genetics and 11 papers in Oncology. Recurrent topics in Christophe Quéva's work include Chronic Lymphocytic Leukemia Research (11 papers), Virus-based gene therapy research (9 papers) and Lymphoma Diagnosis and Treatment (6 papers). Christophe Quéva is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Virus-based gene therapy research (9 papers) and Lymphoma Diagnosis and Treatment (6 papers). Christophe Quéva collaborates with scholars based in United States, France and United Kingdom. Christophe Quéva's co-authors include Robert N. Eisenman, Peter J. Hurlin, D. Stéhelin, Bernard Vandenbunder, Qingshan Yang, Varsha Gandhi, Terry Newcomb, Xavier Desbiens, Kevin P. Foley and Donald E. Ayer and has published in prestigious journals such as Journal of Biological Chemistry, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Christophe Quéva

42 papers receiving 1.7k citations

Peers

Countries citing papers authored by Christophe Quéva

Since Specialization

Citations

This map shows the geographic impact of Christophe Quéva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Quéva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Quéva more than expected).

Fields of papers citing papers by Christophe Quéva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Quéva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Quéva. The network helps show where Christophe Quéva may publish in the future.

Co-authorship network of co-authors of Christophe Quéva

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Quéva. A scholar is included among the top collaborators of Christophe Quéva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Quéva. Christophe Quéva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression 2023 ·Molecular Therapy — Oncolytics ·(unknown), Jennifer S. Lee, (unknown), (unknown), (unknown), (unknown), Christophe Quéva, Lorena Lerner, Edward M. Kennedy	2
2	ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity 2020 ·Cancer Immunology Research ·Brian B. Haines, (unknown), (unknown), Jennifer S. Lee, (unknown), (unknown), (unknown), Lingxin Kong, Prajna Behera, (unknown), (unknown), Michael Ball, (unknown), (unknown), (unknown), Sonia Feau, Edward M. Kennedy, Lorena Lerner, Christophe Quéva	54
3	Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability 2020 ·Molecular Therapy — Oncolytics ·Edward M. Kennedy, (unknown), (unknown), Jennifer S. Lee, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Damian G. Deavall, James B. Rottman, Joseph C. Glorioso, Mitchell Finer, Brian B. Haines, Christophe Quéva, Lorena Lerner	20
4	Oncolytic HSV Vectors and Anti-Tumor Immunity 2020 ·Current Issues in Molecular Biology ·Joseph C. Glorioso, Justus B. Cohen, William F. Goins, Bonnie L. Hall, Joseph W. Jackson, Gary Kohanbash, Nduka Amankulor, Balveen Kaur, Michael A. Caligiuri, E. Antonio Chiocca, Eric C. Holland, Christophe Quéva	15
5	Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9 2019 ·Neuro-Oncology ·Hans‐Georg Wirsching, Sonali Arora, Huajia Zhang, Frank Szulzewsky, Patrick J. Cimino, Christophe Quéva, A. McGarry Houghton, Joseph C. Glorioso, Michael Weller, Eric C. Holland	8
6	Géographie des espaces ruraux 2018 ·SPIRE - Sciences Po Institutional REpository ·(unknown), Christophe Quéva	2
7	PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors 2017 ·PLoS ONE ·(unknown), Sarah Meadows, Rick Sorensen, Zhi-Hua Cui, Kathleen S. Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey Tannheimer	38
8	Retours à l’Est : quelle durabilité pour les territoires à l’Est de l’Allemagne ? 2016 ·Bulletin de l Association de géographes français ·Christophe Quéva	0
9	Innovations sociales et développement des territoires dans les campagnes européennes 2016 ·HAL (Le Centre pour la Communication Scientifique Directe) ·(unknown), Christophe Quéva	1
10	Peptibodies: A flexible alternative format to antibodies 2012 ·mAbs ·Grant Shimamoto, Colin V. Gegg, T. Boone, Christophe Quéva	81
11	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies 2009 ·Investigational New Drugs ·Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, Anne van Abbema, Carlos M. Chavez, Ping Wang, Orit Foord, (unknown), Naomi Laing, (unknown), Shenghua Wen, Larry L. Green, Xiaodong Yang, Carl I. Webster, Ross Stewart, David C. Blakey	20
12	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies 2008 ·Molecular Cancer Therapeutics ·Sonya Zabludoff, Chun Deng, Michael Grondine, (unknown), Susan Ashwell, Benjamin Caleb, Stephen Green, (unknown), Candice L. Horn, James W. Janetka, Dongfang Liu, Elizabeth Mouchet, Shannon Ready, (unknown), Christophe Quéva, Gary K. Schwartz, Karen J. Taylor, Archie Tse, Graeme E. Walker, (unknown)	333
13	Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases 2007 ·Molecular Cancer Therapeutics ·Susan Ashwell, Benjamin Caleb, Chun Deng, Stephen Green, Michael Grondine, (unknown), Candice L. Horn, James W. Janetka, Dongfang Liu, Elizabeth Mouchet, Shannon Ready, (unknown), Christophe Quéva, Karen J. Taylor, (unknown), Graeme E. Walker, (unknown), Sonya Zabludoff	3
14	Development of a New Fully Human Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies. 2007 ·Blood ·Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, (unknown), Carlos Chávez, Ping Wang, Naomi Laing, (unknown), Shenghua Wen, (unknown), Larry L. Green, Xiaodong Yang, David C. Blakey	1
15	Effects of GABA agonists on body temperature regulation in GABA_B(1)^−/− mice 2003 ·British Journal of Pharmacology ·Christophe Quéva, (unknown), A. Edlund, A. Jonas Ekstrand, Susanne Elg, Sven Erickson, (unknown), Anders Lehmann, Jan P. Mattsson	100
16	Sequential expression of the MAD family of transcriptional repressors during differentiation and development 1998 ·Oncogene ·Christophe Quéva, Peter J. Hurlin, Kevin P. Foley, Robert N. Eisenman	109
17	Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. 1997 ·Genes & Development ·Peter J. Hurlin, Christophe Quéva, Robert N. Eisenman	208
18	Mnt: A Novel Max-interacting Protein and Myc Antagonist 1997 ·Current topics in microbiology and immunology ·Peter J. Hurlin, Christophe Quéva, Robert N. Eisenman	33
19	Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion? 1994 ·PubMed ·Bernard Vandenbunder, Nicolas Wernert, Christophe Quéva, Xavier Desbiens, D. Stéhelin	39
20	p54c-ets-1 and p68c-ets-1, the two transcription factors encoded by the c-ets-1 locus, are differentially expressed during the development of the chick embryo. 1993 ·PubMed ·Christophe Quéva, Dominique Leprince, D. Stéhelin, Bernard Vandenbunder	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact